# Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer

> **NCT07155629** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Helsinki University Central Hospital** · enrollment: 381 (estimated)

## Conditions studied

- Pancreatic Cancer Resectable

## Interventions

- **DRUG:** mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine

## Key facts

- **NCT ID:** NCT07155629
- **Lead sponsor:** Helsinki University Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2030-08-31
- **Final completion:** 2030-08-31
- **Target enrollment:** 381 (ESTIMATED)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07155629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07155629, "Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07155629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*